Welcome to Idorsia

Idorsia announced
results for the first
nine months of 2018

When should we be celebrating our birthday?

Read about how Idorsia was born…

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.

Idorsia’s future success entirely depends on our people.

Idorsia's development compounds target a number of different diseases.

20 Nov 2018	Santhera enters into agreement to acquire option from Idorsia for exclusive sub-license of first-in-class dissociative steroid vamorolone
05 Nov 2018	Idorsia maintains collaboration agreement with ReveraGen
24 Oct 2018	Company statement

Event	When
Full-Year 2018 Financial Results reporting*	February 7, 2019
First Quarter 2019 Financial Results reporting*	April 18, 2019
Annual General Meeting 2019	May 3, 2019
Half-Year 2019 Financial Results reporting*	July 23, 2019

*We will be in a silent period for 10 days ahead of the financial reporting.

IDIA SIX Swiss Exchange

At 16:13:28 CET

18.38 CHF

+0.15 (+0.82 %)

Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91

4123 Allschwil

Switzerland